CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 121 enrolled
Drug / intervention
U3-1402drug
Likely dose
U3-1402 5.6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04699630
NCT04699630Phase 2Completed
CompareCT.gov

A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer

SCRI Development Innovations, LLC·interventional·Posted Jan 7, 2021·Updated May 22, 2026

In Brief

A Phase 2 clinical trial evaluating U3-1402 for Metastatic Breast Cancer and Locally Advanced Breast Cancer. Completed, enrolled 121 participants across 11 sites.

Detailed Summary

This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer, Locally Advanced Breast Cancer
CountriesUnited States
CollaboratorsDaiichi Sankyo

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJan 7, 2021
Enrollment StartMay 3, 2021
Primary CompletionApr 9, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.5 years ago

Interventions

U3-1402drug

All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.